AlphAIAlphAI — Financial news for AI agents
investing.comSEP 162 min read$TWST

Why is Twist Bioscience stock rallying today?

Twist Bioscience (TWST) stock rose 3.7% after joining Eli Lilly's TuneLab platform as a preferred antibody data provider. The deal supports Twist's AI-driven life science strategy, following record Q3 revenue and raised guidance. The stock is near its 52-week high, with NASDAQ and S&P 500 also gaining.

Original reporting
investing.com
Published Sep 16, 2026, 6:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 6:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$TWST
Bullish
high confidence
Mentioned
$TWST
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TWSTBullishMed
01

Why it matters

Twist's AI partnership could accelerate its growth trajectory and attract further collaborations.

02

Market read

The announcement drives immediate price action and signals broader AI‑biotech convergence.

03

What to watch

Execution risk and dependence on Lilly's platform adoption timeline.

Relevance 7/10Novelty 8/10Timing: afternoon today

Background

Fed rate hike backdrop and overall market risk‑on tone supported the stock's move.

Company-level read

Ticker impact

$TWSTBullishHigh confidence
Context

Twist Bioscience announced a new partnership with Eli Lilly's TuneLab platform, driving a 3.7% rally in afternoon trading.

Expected impact

Potential further upside as the collaboration expands and attracts additional biotech partners.

Evidence & confidence

First disclosure of a high‑profile Lilly partnership; early market reaction already positive, indicating strong trader interest.

Market effects

Sector

Highlights growing AI adoption in biotech, may benefit peers like Schrödinger.

Regional

U.S. biotech sector sees modest uplift.

Global

Shows cross‑border collaboration between U.S. biotech and multinational pharma.

Counterpoint

What could challenge this read

Partnership may not translate into immediate revenue if integration challenges arise.

Key entities

  • company
    Twist Bioscience

    US-listed biotech providing high‑throughput antibody data.

  • company
    Eli Lilly

    Pharma partner offering the TuneLab AI platform.

Read at source← All news

Also covered by

3 outlets

Related articles

SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

timothysykes.com2 min